|Bid||2.2400 x 9300|
|Ask||2.2500 x 5700|
|Day's Range||2.1000 - 2.4200|
|52 Week Range||0.5000 - 2.4200|
|PE Ratio (TTM)||-5.86|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
AVEO Oncology stock also dropped as much as 12.3% in a wild trading session.
AVEO Pharmaceuticals, Inc. (AVEO) announced on Friday that the Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of its lead candidate, Fotivda (tivozanib), for the treatment of advanced renal cell carcinoma (RCC).
AVEO Pharmaceuticals Inc. shares surged as much as 48% in extremely heavy morning trade Friday after the company's cancer drug was recommended for approval in Europe. The decision was made by a scientific ...